Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7288783 | 0.83 | SIGMAR1 (0.56) | SIGMAR1KMT2AMEN1SLC6A2SLC6A4 | |
| SCHEMBL8267685 | 0.83 | ALDH1A1 (0.69) | ALDH1A1KDM4EGFERL3MBTL1KMT2A | |
| SCHEMBL10649778 | 0.83 | SIGMAR1 (0.56) | SIGMAR1 | |
| SCHEMBL5754011 | 0.83 | SLC6A2 (0.55) | ALDH1A1KDM4EGFERL3MBTL1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL11198718 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KDM4EGFERL3MBTL1SIGMAR1 | |
| SCHEMBL7792404 | 0.81 | ALDH1A1 (0.67) | ALDH1A1KDM4EGFERL3MBTL1KMT2A | |
| SCHEMBL8470235 | 0.81 | SLC6A4 (0.47) | ALDH1A1KDM4EGFERL3MBTL1SIGMAR1 | |
| SCHEMBL8470238 | 0.81 | SLC6A4 (0.47) | ALDH1A1KDM4EGFERL3MBTL1SIGMAR1 | |
| SCHEMBL10901707 | 0.81 | OPRD1 (0.54) | ALDH1A1KDM4EGFERL3MBTL1KMT2A | |
| SCHEMBL469006 | 0.80 | SIGMAR1 (0.47) | ALDH1A1KDM4EGFERL3MBTL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | claimed |
| EP-4561994-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | Genecode (EE) | 2025-06-04 | — | — | EP | claimed |
| CN-119948015-A | Novel sulfonamides and their use as neuroprotective and/or nerve repair agents | 基因密码公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2024023284-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2024-02-01 | — | — | WO | claimed |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| EP-4561994-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | Genecode (EE) | 2025-06-04 | — | — | EP | disclosed |
| CN-119948015-A | Novel sulfonamides and their use as neuroprotective and/or nerve repair agents | 基因密码公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2024023284-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2024-02-01 | — | — | WO | disclosed |
| EP-2509600-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-0906318-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997045432-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-04 | — | — | WO | disclosed |
| US-4374990-A | ANTIDEPRESSANTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-22 | — | — | US | disclosed |
| US-4259334-A | Piperazines and therapeutic utility | LAROCHE NAVARRON S.A. (FR) | 1981-03-31 | — | — | US | disclosed |
| US-4115569-A | PARASITICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | ALDH1A1 1383/4885KDM4E 4619/4885GFER 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.